000007492 001__ 7492
000007492 005__ 20231129124941.0
000007492 0247_ $$2DOI$$a10.6083/fj236261b
000007492 037__ $$aETD
000007492 245__ $$aTLR7 as a therapeutic target for pancreatic ductal adenocarcinoma and cancer-associated cachexia
000007492 260__ $$bOregon Health and Science University
000007492 269__ $$a2019
000007492 336__ $$aDissertation
000007492 502__ $$bPh.D.
000007492 520__ $$aPancreatic ductal adenocarcinoma (PDAC) is among the deadliest of malignancies, with a dismal survival rate and limited treatment options. Advances in therapeutic modalities are urgently needed not only to successfully restrain tumor growth, but to address the underlying physiological aberrations that drive significant morbidity and mortality in PDAC. Specifically, no therapies exist to treat cachexia, a complex metabolic and behavioral syndrome that is present in up to 85% of patients with PDAC. To address this therapeutic gap, I performed three main studies detailed over the course of this dissertation.
000007492 542__ $$fIn copyright - single owner
000007492 650__ $$aImmune Tolerance$$020667
000007492 650__ $$aAdenocarcinoma$$014225
000007492 650__ $$aCachexia$$015945
000007492 650__ $$aImmunotherapy$$020724
000007492 650__ $$aImmunity$$020668
000007492 650__ $$aPhysiology$$024123
000007492 650__ $$aSystems Biology$$036214
000007492 6531_ $$apancreatic ductal carcinomas
000007492 6531_ $$ainnate
000007492 6531_ $$aimmunology
000007492 691__ $$aSchool of Medicine$$041369
000007492 692__ $$aDepartment of Physiology and Pharmacology$$041442
000007492 7001_ $$aMichaelis, Katherine A.
000007492 8564_ $$93827bdbc-770c-4b92-8438-04ca12044e3d$$s17536762$$uhttps://digitalcollections.ohsu.edu/record/7492/files/michaelis.katherine.2019.pdf
000007492 905__ $$a/rest/prod/fj/23/62/61/fj236261b
000007492 909CO $$ooai:digitalcollections.ohsu.edu:7492$$pstudent-work
000007492 980__ $$aTheses and Dissertations